Glycaemic outcomes of an Individualized treatMent aPproach for oldER vulnerable patIents: A randomized, controlled stUdy in type 2 diabetes Mellitus (IMPERIUM)

To compare the glycaemic outcomes of 2 glucose‐lowering treatment strategies in vulnerable (moderately ill and/or frail) patients aged ≥65 years with type 2 diabetes whose individual HbA1c targets were not met with diet/exercise and/or oral anti‐hyperglycaemic medications (OAMs).

[1]  Jørgen K. Kanters,et al.  Patients With Long-QT Syndrome Caused by Impaired hERG-Encoded Kv11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia , 2017, Circulation.

[2]  J. Shaw,et al.  IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. , 2011, Diabetes research and clinical practice.

[3]  J. Holst,et al.  Critical role for GLP-1 in symptomatic post-bariatric hypoglycaemia , 2017, Diabetologia.

[4]  Robert A. Vigersky,et al.  Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes , 2016, Diabetologia.

[5]  Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2016, Diabetes Care.

[6]  M. Nauck,et al.  Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors , 2016, Diabetes, obesity & metabolism.

[7]  M. Hoshen,et al.  Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists , 2015, Diabetes Care.

[8]  E. Bartoli,et al.  Sulfonylureas and their use in clinical practice , 2015, Archives of medical science : AMS.

[9]  M. Jiroutek,et al.  Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists. , 2015, Clinical therapeutics.

[10]  U. Sambamoorthi,et al.  A Real‐World Study of the Effect of Timing of Insulin Initiation on Outcomes in Older Medicare Beneficiaries with Type 2 Diabetes Mellitus , 2015, Journal of the American Geriatrics Society.

[11]  A. Sinclair,et al.  Diabetes in older people: new insights and remaining challenges. , 2015, The lancet. Diabetes & endocrinology.

[12]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2014, Diabetes Care.

[13]  FuHaoda,et al.  Treatment Patterns Among Older Patients with Type 2 Diabetes in the United States: A Retrospective Cohort Study , 2014 .

[14]  E. Beverly,et al.  Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options , 2014, Clinical interventions in aging.

[15]  L. Arnold,et al.  The HbA1c and all-cause mortality relationship in patients with type 2 diabetes is J-shaped: a meta-analysis of observational studies. , 2014, The review of diabetic studies : RDS.

[16]  S. Heller,et al.  Treatment of type 2 diabetes mellitus in the older adult: a review. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[17]  Alan Bernjak,et al.  Risk of Cardiac Arrhythmias During Hypoglycemia in Patients With Type 2 Diabetes and Cardiovascular Risk , 2014, Diabetes.

[18]  M. Hanefeld,et al.  Relationship Between Hypoglycemic Episodes and Ventricular Arrhythmias in Patients With Type 2 Diabetes and Cardiovascular Diseases: Silent Hypoglycemias and Silent Arrhythmias , 2014, Diabetes Care.

[19]  H. Fu,et al.  Treatment patterns among older patients with type 2 diabetes in the United States: a retrospective cohort study. , 2014, Diabetes technology & therapeutics.

[20]  F. Wolf,et al.  Standards of Medical Care in Diabetes—2016 Abridged for Primary Care Providers , 2016, Clinical Diabetes.

[21]  A. Sinclair,et al.  Frailty and diabetes , 2013, The Lancet.

[22]  A. Tahrani,et al.  SGLT inhibitors in management of diabetes. , 2013, The lancet. Diabetes & endocrinology.

[23]  Nathaniel Clark,et al.  Diabetes in Older Adults: A Consensus Report , 2012, Journal of the American Geriatrics Society.

[24]  Nathaniel Clark,et al.  Diabetes in Older Adults , 2012, Diabetes Care.

[25]  Suzanne L West,et al.  Initial and subsequent therapy for newly diagnosed type 2 diabetes patients treated in primary care using data from a vendor‐based electronic health record , 2012, Pharmacoepidemiology and drug safety.

[26]  Sei J. Lee,et al.  Glycosylated Hemoglobin and Functional Decline in Community‐Dwelling Nursing Home–Eligible Elderly Adults with Diabetes Mellitus , 2012, Journal of the American Geriatrics Society.

[27]  A. Sinclair,et al.  Diabetes mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), the European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. , 2012, Journal of the American Medical Directors Association.

[28]  Gangyi Yang,et al.  Glucagon‐like peptide‐1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta‐analysis of clinical trials , 2011, Diabetes, obesity & metabolism.

[29]  Sei J. Lee,et al.  Goals of glycemic control in frail older patients with diabetes. , 2011, JAMA.

[30]  J. Shaw,et al.  IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. , 2011, Diabetes research and clinical practice.

[31]  S. Kaplan,et al.  Comorbidity Affects the Relationship Between Glycemic Control and Cardiovascular Outcomes in Diabetes , 2009, Annals of Internal Medicine.

[32]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[33]  Frank A Sloan,et al.  The growing burden of diabetes mellitus in the US elderly population. , 2008, Archives of internal medicine.

[34]  S. Gambert,et al.  Emerging Epidemic: Diabetes in Older Adults: Demography, Economic Impact, and Pathophysiology , 2006 .

[35]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[36]  I. McDowell,et al.  A global clinical measure of fitness and frailty in elderly people , 2005, Canadian Medical Association Journal.

[37]  M. Burge,et al.  Hypoglycaemia in Elderly Patients with Diabetes Mellitus , 2004 .

[38]  M. Burge,et al.  Hypoglycaemia in elderly patients with diabetes mellitus: causes and strategies for prevention. , 2004, Drugs & aging.

[39]  M. Goolsby.  National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, Journal of the American Academy of Nurse Practitioners.

[40]  Kdoqi Disclaimer.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[41]  F. Ashcroft.  Mechanisms of the Glycaemic Effects of Sulfonylureas , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.